pmedpharmФармация и фармакологияPharmacy & Pharmacology2307-92662413-2241Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer10.19163/2307-9266-2020-8-3-160-168pmedpharm-710Research ArticleФАРМАКОЛОГИЯ И КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯPHARMACOLOGY AND CLINICAL PHARMACOLOGYКЛИНИКО-ИММУНОЛОГИЧЕСКАЯ ЭФФЕКТИВНОСТЬ РИБОМУНИЛА У ДЕТЕЙ С ВИРУС-ИНДУЦИРОВАННОЙ БРОНХИАЛЬНОЙ АСТМОЙCLINICAL-IMMUNOLOGICAL EFFECTIVENESS OF RIBOMUNYL IN CHILDREN WITH VIRUS-INDUCED BRONCHIAL ASTHMAhttps://orcid.org/0000-0003-2674-4289БеланЭ. Б.BelanE. B.

Белан Элеонора Борисовна – доктор медицинских наук, профессор, заведующий кафедрой иммунологии и аллергологии 

400131, г. Волгоград, площадь Павших Борцов, д. 1

Eleonora B. Belan – Doctor of Sciences (Medicine), Professor, the Head of the Department of Immunology and Allergology 

1, Pavshikh Bortsov Sq., Volgograd, 400131

belan.eleonora@yandex.ruhttps://orcid.org/0000-0003-1475-9301НикифороваЕ. М.NikiforovaE. M.

Никифорова Елизавета Михайловна – кандидат медицинских наук, доцент, доцент кафедры иммунологии и аллергологии 

400131, г. Волгоград, площадь Павших Борцов, д. 1

Elizaveta M. Nikiforova – Candidate of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Immunology and Allergology 

1, Pavshikh Bortsov Sq., Volgograd, 400131

maior10@yandex.ruhttps://orcid.org/0000-0001-6758-4686ЗаячниковаТ. Е.ZayachnikovaT. E.

Заячникова Татьяна Евгеньевна – кандидат медицинских наук, доцент, профессор кафедры педиатрии и неонатологии Института непрерывного медицинского и фармацевтического образования 

400131, г. Волгоград, площадь Павших Борцов, д. 1

Tatyana E. Zayachnikova – Doctor of Sciences (Medicine), Associate Professor, Professor of the Department of Pediatrics and Neonatology of the Institute of Continuous Medical and Pharmaceutical Education 

1, Pavshikh Bortsov Sq., Volgograd, 400131

guz5deti@mail.ruhttps://orcid.org/0000-0001-6098-7028ШишиморовИ. Н.ShishimorovL. N.

Шишиморов Иван Николаевич – доктор медицинских наук, доцент, заведующий кафедрой педиатрии и неонатологии Института непрерывного медицинского и фармацевтического образования 

400131, г. Волгоград, площадь Павших Борцов, д. 1

Ivan N. Shishimorov – Doctor of Sciences (Medicine), Associate Professor, the Head of the Department of Pediatrics and Neonatology of the Institute of Continuous Medical and Pharmaceutical Education 

1, Pavshikh Bortsov Sq., Volgograd, 400131

drshishimorov@gmail.comhttps://orcid.org/0000-0001-6670-9029МагницкаяО. В.MagnitskayaO. V.

Магницкая Ольга Валерьевна – доктор медицинских наук, доцент, профессор кафедры педиатрии и неонатологии Института непрерывного медицинского и фармацевтического образования 

400131, г. Волгоград, площадь Павших Борцов, д. 1

Olga V. Magnitskaya – Doctor of Sciences (Medicine), Associate Professor, Professor of the Department of Pediatrics and Neonatology of the Institute of Continuing Medical and Pharmaceutical Education 

1, Pavshikh Bortsov Sq., Volgograd, 400131

magol73@ya.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияVolgograd State Medical UniversityRussian Federation20202112202083160168Copyright © Белан Э.Б., Никифорова Е.М., Заячникова Т.Е., Шишиморов И.Н., Магницкая О.В., 20202020Белан Э.Б., Никифорова Е.М., Заячникова Т.Е., Шишиморов И.Н., Магницкая О.В.Belan E.B., Nikiforova E.M., Zayachnikova T.E., Shishimorov l.N., Magnitskaya O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmpharm.ru/jour/article/view/710Цель

Цель: изучить клинико-иммунологическую эффективность рибомунила у детей с вирус-индуцированной бронхиальной астмой (БА).

Материалы и методы

Материалы и методы. 14 детей с вирус-индуцированной БА получали в составе комплексной терапии препарат рибомунил (3 курса, 18 месяцев); группу сравнения составили 16 больных, получавших только стандартную терапию вирус-индуцированной БА. На момент окончания исследования у детей оценивали на фоне базисной терапии БА частоту острых респираторных вирусных инфекций (ОРВИ), потребность в антибактериальной терапии, частоту определения иммуноглобулина G (IgG) к респираторно-синцитиальному вирусу (РСВ), динамику сывороточного уровня общего IgE, интерлейкина-4 (IL-4), интерферона-гамма (ИФНγ).

Результаты

Результаты. Включение рибомунила в терапевтический комплекс при вирус-индуцированной БА у детей позволило в 50% случаев и 12,5% (р=0,0279) снизить потребность в базисной терапии БА. В то же время частота ОРВИ сопоставимо уменьшилась в обеих группах, однако в основной группе снизилось с 78,6% до 42,9% (р=0,0199) количество случаев, требующих назначения антибактериальной терапии. Включение рибомунила в терапевтический комплекс привело к снижению сывороточного уровня общего IgE; у больных с исходным наличием IgG к РС-вирусу снизился уровнь IL-4 и повысился уровень ИФНγ.

Заключение

Заключение. Рибомунил улучшает течение вирус-индуцированной БА у детей, при этом динамика иммунологических показателей более выражена у РСВ-серопозитивных пациентов.

The aim of the study is to research the effects of immunostimulant Ribomunyl in virus-induced bronchial asthma (VBA) children.

Materials and methods

Materials and methods. 14 virus-induced bronchial asthma (VBA) children were agministrated with immunostimulant Ribomunyl as a part of complex therapy in a 18-month trial (3 cycles of treatment). The comparison group consisted of 16 patients who received only standard therapy for bronchial asthma. At the end of the study, against the background of basic BA therapy, the following parameters were estimated: the frequency of acute respiratory viral infections (ARVI), the need for antibacterial therapy, the frequency of IgG to respiratory-syncytial virus (RSV) prevalence, the serum level dynamics of total IgE, IFN-γ, interleukin-4 (IL-4), interferon gamma (IFN-γ).

Results

Results. The inclusion of Ribomunyl into the basic therapy complex in virus-induced bronchial asthma (VBA) children, made it possible to reduce the need for the VBA basic therapy complex by 50% and by 12,5% (р=0,0279). At the same time, as for the frequency of acute respiratory viral infections (ARVI), there was a comparable decrease in both groups, but in the main group the number of cases requiring antibiotic therapy decreased from 78.6% to 42.9% (p=0.0199). The inclusion of Ribomunyl into the basic therapy complex resulted in the decrease of the total IgE serum level; in the patients with the initial presence of IgG to the respiratory syncytial virus (RSV), the IL-4 level decreased and the IFN-γ level increased.

Conclusion

Conclusion. Ribomunyl improves the treatment of virus-induced bronchial asthma (VBA) children, herewith the dynamics of immunological indicators is more in RSV-seropositive patients.

бронхиальная астмадетирибомунилвирус-индуцированная БАbronchial asthmachildrenRibomunylvirus-induced bronchial asthmaReferencesФедеральные клинические рекомендации «Бронхиальная астма у детей». – Москва, 2019. 76 с.[Federal’nye klinicheskie rekomendacii «Bronhial’naja astma u detej]. Moscow. 2019. 76p. RussianThe Global Asthma Report 2018. – URL: Available online: http://globalasthmareport.org/Global Asthma Report 2018.pdf (дата обращения 22.03. 2019).The Global Asthma Report 2018. Available from: http://globalasthmareport.org/Global Asthma Report 2018.pdf (date of the application: 2019 March 22). RussianLe Souëf P. Viral infections in wheezing disorders // European Respiratory Review. 2018. Vol. 27. P. 170133. DOI: 10.1183/16000617.0133-2017.Le Souëf P. Viral infections in wheezing disorders. European Respiratory Review. 2018;27:170133. DOI: 10.1183/16000617.0133-2017.Mikhail I., Grason M. Asthma and viral infections: An intricate relationship // Annals of Allergy, Asthma & Immunology. 2019. Vol. 123. No4. P. 352–358. DOI: 10.1016/j.anai.2019.06.020.Mikhail I, Grason M. Asthma and viral infections: An intricate relationship. Annals of Allergy, Asthma & Immunology. 2019;123(4):352–358. DOI: 10.1016/j.anai.2019.06.020.Del-Rio-Navarro B.E., Espinosa-Rosales F.J., Flenady V., Sienra-Monge J.J.L. Cochrane Review: Immunostimulants for preventing respiratory tract infection in children // Evidence-Based Child Health: A Cochrane Review Journal. 2012. Vol. 7. No2. P. 629–717. DOI: 10.1002/ebch.1833.Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJL. Cochrane Review: Immunostimulants for preventing respiratory tract infection in children. Evidence-Based Child Health: A Cochrane Review Journal. 2012;7(2):629–717. DOI: 10.1002/ebch.1833.Esposito S., Soto-Martinez E.M., Feleszko W., Jones M.H., Kun-Ling Shen, Schaad Urs B. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence // Current Opinion in Allergy and Clinical Immunology. 2018. Vol. 18. No3. P. 198–209. DOI: 10.1097/ACI.0000000000000433.Esposito S, Soto-Martinez EM, Feleszko W, Jones MH, Kun-Ling Shen, Schaad Urs B. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Current Opinion in Allergy and Clinical Immunology. 2018;18(3):198–209. DOI: 10.1097/ACI.0000000000000433.Esposito S., Bianchini S., Polinori I., Principi N. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study // International Journal of Environmental Research and Public Health. 2019. Vol. 16. No6. P. 1065. DOI: 10.3390/ijerph16061065.Esposito S, Bianchini S, Polinori I, Principi N. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study. International Journal of Environmental Research and Public Health. 2019;16(6):1065. DOI: 10.3390/ijerph16061065.Hamill P., Brown K., Jenssen H., Hancock R.E. Novel antiinfectives: is host defence the answer? // Current Opinion in Biotechnology. 2008. Vol. 19. No6. P. 628–636. DOI: 10.1016/j.copbio.2008.10.006.Hamill P, Brown K, Jenssen H, Hancock RE. Novel anti-infectives: is host defence the answer? Current Opinion in Biotechnology. 2008;19(6):628–636. DOI: 10.1016/j.copbio.2008.10.006.Tejera-Alhambra M., Palomares O., Perez de Diego R., DiazLezcano I., Sanchez-Ramon S. New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice // Current Pharmaceutcal Design. 2016. Vol. 22. No41. P. 6283–6293. DOI: 10.2174/1381612822666160829143129.Tejera-Alhambra M, Palomares O, Perez de Diego R, Diaz-Lezcano I, Sanchez-Ramon S. New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice. Current Pharmaceutcal Design. 2016;22(41):6283–6293. DOI: 10.2174/1381612822666160829143129.ПРИМА: педиатрические рекомендации по иммуномодулирующим препаратам в амбулаторной практике: (консенсус) / Педиатр. респиратор. о-во, Рос. ассоц. аллергологов и клинич. иммунологов, Моск. о-во дет. врачей, Федерация педиатров стран СНГ [и др.]. 2-е изд., перераб. и доп. – Москва: РГ-Пресс, 2017. 76 с.[PRIMA: pediatricheskie rekomendacii po immunomodulirujushhim preparatam v ambulatornoj praktike: (konsensus) / Pediatr. respirator. o-vo, Ros. assoc. allergologov i klinich. immunologov, Mosk. o-vo det. vrachej, Federacija pediatrov stran SNG [i dr.]. 2-e izd., pererab. i dop.] Moscow.: RG-Press. 2017. 76 p. RussianHerberhold S., Coch C., Zillinger T., Hommertgen B., Busch N., Schuberth C., Hartmann E., Wimmenauer V., Hagmann C.A., Lüdenbach B., Schlee M., Bootz F., Hartmann G., Barchet W. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Tolllike receptor 7/8 agonist // Antiviral Therapy. 2011. Vol. 16. No5. P. 751–758. DOI: 10.3851/IMP1822.Herberhold S, Coch C, Zillinger T, Hommertgen B, Busch N, Schuberth C, Hartmann E, Wimmenauer V, Hagmann CA, Lüdenbach B, Schlee M, Bootz F, Hartmann G, Barchet W. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist. Antiviral Therapy. 2011;16(5):751–758. DOI:10.3851/IMP1822.Lynch J.P., Mazzone S.B., Rogers M.J., Arikkatt J.J., Loh Z., Pritchard A.L., Upham J.W., Phipps S. The plasmacytoid dendritic cell: at the cross-roads in asthma // European Respiratory Journal. 2014. Vol. 43. No1. P. 264–275. DOI: 10.1183/09031936.00203412.Lynch JP, Mazzone SB, Rogers MJ, Arikkatt JJ, Loh Z, Pritchard AL, Upham JW, Phipps S. The plasmacytoid dendritic cell: at the cross-roads in asthma. European Respiratory Journal. 2014;43(1):264–275. DOI: 10.1183/09031936.00203412.Matricardi P.M., Bjorksten B., Bonini S., Bousquet J., Djukanovic R., Dreborg S., Gereda J., Malling H.-J., Popov T., Raz E., Renz H. Microbial products in allergy prevention and therapy // Allergy. 2003. Vol.58. P. 461–471. DOI: 10.1034/j.1398-9995.2003.00175.x.Matricardi PM, Bjorksten B, Bonini S, Bousquet J, Djukanovic R, Dreborg S, Gereda J, Malling H.-J, Popov T, Raz E, Renz H. Microbial products in allergy prevention and therapy. Allergy. 2003;58:461–471. DOI: 10.1034/j.1398-9995.2003.00175.x.Просекова Е.В., Деркач В.В., Шестовская Т.Н., Сергиенко И.С. Влияние бронхомунала на цитокиновый профиль сыворотки крови детей с бронхиальной астмой // Актуальные вопросы аллергических заболеваний: сб. тезисов III Региональной научно-практической конференции. – Владивосток, 2005. С. 58.Prosekova EV, Derkach VV, Shestovskaja TN, Sergienko IS. [Vlijanie bronhomunala na citokinovyj profil’ syvorotki krovi detej s bronhial’noj astmoj. Aktual’nye voprosy allergicheskih zabolevanij: sb. tezisov III Regional’noj nauchno-prakticheskoj konferencii]. Vladivostok, 2005:58p. RussianBystron J., Hermanova Z., Szotkovska J., Heller L., Pazderova D. Effect of Ribosomal Immunotherapy on the Clinical Condition and Plasma Levels of Cytokines IL-4, IL-5, IL-12 and IFNgamma and Total IgE in Patients with Seasonal Allergy during the Pollen Season // Clinical Drug Investigation. 2004. Vol. 24. No12. Р. 761–764. DOI: 10.2165/00044011-200424120-00007.Bystron J, Hermanova Z, Szotkovska J, Heller L, Pazderova D. Effect of Ribosomal Immunotherapy on the Clinical Condition and Plasma Levels of Cytokines IL-4, IL-5, IL-12 and IFNgamma and Total IgE in Patients with Seasonal Allergy during the Pollen Season. Clinical Drug Investigation. 2004;24(12):761–764. DOI: 10.2165/00044011-200424120-00007.Hbabi-Haddioui L., Roques C. Inhibition of Streptococcus pneumonia adhesion by specific salivary IgA after ora immunostimulation with a ribosomal immunostimulant // Drugs. 1997. Vol. 54. Р. 29–32. DOI: 10.2165/00003495-199700541-00008.Hbabi-Haddioui L, Roques C. Inhibition of Streptococcus pneumonia adhesion by specific salivary IgA after oral immunostimulation with a ribosomal immunostimulant. Drugs. 1997;54:29–32. DOI: 10.2165/00003495-199700541-00008.Barr R., Green C.A., Sande C.J., Drysdale S.B. Respiratory syncytial virus: diagnosis, prevention and management // Therapeutic Advances in Infectious Disease. 2019. Vol. 6. P:2049936119865798. DOI: 10.1177/2049936119865798.Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis, prevention and management. Therapeutic Advances in Infectious Disease. 2019;6:2049936119865798. DOI: 10.1177/2049936119865798.Green C.A., Yeates D., Goldacre A., Sande C., Parslow R.C., McShane P., Pollard A.J., Goldacre M.J. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma // Archives of Disease in Childhood. 2016. Vol. 101. No2. P. 140–146. DOI: 10.1136/archdischild-2015-308723.Green CA, Yeates D, Goldacre A, Sande C, Parslow RC, McShane P, Pollard AJ, Goldacre MJ. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Archives of Disease in Childhood. 2016;101(2):140–146. DOI: 10.1136/archdischild-2015-308723.Ralston S.L., Lieberthal A.S., Meissner H.C. et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis // Pediatrics. 2014. Vol. 134. No5. P. e1474–e1502. DOI: 10.1542/peds.2014-2742.Ralston SL, Lieberthal AS, Meissner HC. et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. DOI: 10.1542/peds.2014-2742.Bont L., Checchia P.A., Fauroux B., Figueras-Aloy J., Manzoni P., Paes B., Simões E.A., Carbonell-Estrany X. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries // Infectious Diseases and Therapy. 2016. Vol. 5. No3. P. 271–298. DOI: 10.1007/s40121-016-0123-0.Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Carbonell-Estrany X. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infectious Diseases and Therapy. 2016;5(3):271–298. DOI: 10.1007/s40121-016-0123-0.Shi T., McAllister D.A., O’Brien K.L. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study // Lancet. 2017. Vol. 390. No10098. P. 946–958. DOI: 10.1016/S0140-6736(17)30938-8.Shi T, McAllister DA, O’Brien KL. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. DOI: 10.1016/S0140-6736(17)30938-8.Cromer D., van Hoek A.J., Newall A.T., Polard A.J., Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and costeffectiveness analysis for England // The Lancet Public Health. 2017. Vol. 2. No8. P. e367–e374. DOI: 10.1016/S2468-2667(17)30103-2.Cromer D, van Hoek AJ, Newall AT, Polard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and costeffectiveness analysis for England. The Lancet Public Health. 2017;2(8):e367–e374. DOI: 10.1016/S2468-2667(17)30103-2.Rosas-Salazar C., Gebretsadik T., Anderson L.J., Jadhao S., Chappell J.D., Larkin E.K., Martin L. Moore M.L., Peebles R.S., Hartert T. Risk or Protective Factor? Mild Respiratory Syncytial Virus Infection in Infancy and the Development of Recurrent Childhood Wheeze // American Journal of Respiratory and Critical Care Medicine. 2020. Vol. 201. P. A5028. DOI: 10.1177/2049936119865798.Rosas-Salazar C, Gebretsadik T, Anderson LJ, Jadhao S, Chappell JD, Larkin EK, Martin L. Moore ML, Peebles RS, Hartert T. Risk or Protective Factor? Mild Respiratory Syncytial Virus Infection in Infancy and the Development of Recurrent Childhood Wheeze. American Journal of Respiratory and Critical Care Medicine. 2020;201:A5028. DOI: 10.1177/2049936119865798.Teach S.J., Gill M.A., Togias A., Sorkness C.A., Arbes S.J. Jr. et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations // The Journal of Allergy and Clinical Immunology. 2015. Vol. 136. No6. P.1476-1485. DOI: 10.1016/j.jaci.2015.09.008.Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ. Jr. et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. The Journal of Allergy and Clinical Immunology. 2015;136(6):1476–1485. DOI: 10.1016/j.jaci.2015.09.008.Tam J.S., Jackson W.T., Hunter D., Proud D., Grayson M.H. Rhinovirus specific IgE can be detected in human sera // Journal of Allergy and Clinical Immunology. 2013. Vol. 132. No5. P. 1241–1243. DOI: 10.1016/j.jaci.2013.07.011.Tam JS, Jackson WT, Hunter D, Proud D, Grayson MH. Rhinovirus specific IgE can be detected in human sera. Journal of Allergy and Clinical Immunology. 2013;132(5):1241–1243. DOI: 10.1016/j.jaci.2013.07.011.Glaser L., Coulter P.J., Shields M., Touzelet O., Power U.F., Broadbent L. Airway Epithelial Derived Cytokines and Chemokines and Their Role in the Immune Response to Respiratory Syncytial Virus Infection // Pathogens. 2019. Vol. 8. No3. P. 106. DOI: 10.3390/pathogens8030106.Glaser L, Coulter PJ, Shields M, Touzelet O, Power UF, Broadbent L. Airway Epithelial Derived Cytokines and Chemokines and Their Role in the Immune Response to Respiratory Syncytial Virus Infection. Pathogens. 2019;8(3):106. DOI: 10.3390/pathogens8030106.Bermejo-Martin J.F., Garcia-Arevalo M.C., De Lejarazu R.O., Ardura J., Eiros J.M., Alonso A., Matías V., Pino M., Bernardo D., Arranz E., Blanco-Quiros A. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children // European Cytokine Network. 2007. Vol. 18. No3. P. 162–167. DOI: 10.1684/ecn.2007.0096.Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, Ardura J, Eiros JM, Alonso A, Matías V, Pino M, Bernardo D, Arranz E, Blanco-Quiros A. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. European Cytokine Network. 2007;18(3):162–167. DOI: 10.1684/ecn.2007.0096.Kaneko H., Matsui E., Asano T., Kato Z., Teramoto T., Aoki M., Kawamoto N., Lian L.A., Kasahara K., Kondo N. Suppression of IFN-gamma production in atopic group at the acute phase of RSV infection // Pediatriac Allergy and Immunology. 2006. Vol. 17. No5. P. 370–375. DOI: 10.1111/j.1399-3038.2006.00419.x.Kaneko H, Matsui E, Asano T, Kato Z, Teramoto T, Aoki M, Kawamoto N, Lian LA, Kasahara K, Kondo N. Suppression of IFN-gamma production in atopic group at the acute phase of RSV infection. Pediatriac Allergy and Immunology. 2006;17(5):370–375. DOI: 10.1111/j.1399-3038.2006.00419.x.Заплатников А.Л., Гирина А.А., Леписева И.В., Коровина Н.А. Рибосомальная иммунотерапия у детей с рекуррентными инфекциями и хроническими заболеваниями органов дыхания: лечебно-профилактическая и экономическая эффективность // Педиатрия. 2017. Т. 96. №2. С. 151–157.Zaplatnikov AL, Girina AA, Lepsieva IV, Korovina NA, Cheburkin AA, Svintsitskaya VI, Coroid NV. Ribosomal immunotherapy in children with recurrent infections and chronic respiratory diseases: preventive and economic efficacy. Pediatria. 2017;96(2):151–157.Kak G., Raza M., Tiwari B.K. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases // Biomolecular Concepts. 2018. Vol. 9. No1. P. 64–79. DOI: 10.1515/bmc-2018-0007.Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomolecular Concepts. 2018;9(1):64–79. DOI: 10.1515/bmc-2018-0007.Hatami H., Ghaffari N., Ghaffari J., Rafatpanah H. Role of Cytokines and Chemokines in the Outcome of Children With Severe Asthma: Narrative Review // Journal of Pediatrics Review. 2019. Vol. 7. No1. P. 17–28. DOI: 10.32598/jpr.7.1.17.Hatami H, Ghaffari N, Ghaffari J, Rafatpanah H. Role of Cytokines and Chemokines in the Outcome of Children with Severe Asthma: Narrative Review. Journal of Pediatrics Review. 2019;7(1):17–28. DOI: 10.32598/jpr.7.1.17.Hussein Y.M., Alzahrani S.S., Alharthi A.A., Ghonaim M.M., Alhazmi A.S., Eed E.M., Shalaby S.M. Association of serum cytokines levels, interleukin 10 -1082G/A and interferon-γ +874T/A polymorphisms with atopic asthma children from Saudi Arabia // Cellular Immunology. 2014. Vol. 289. No1–2. P. 21–26. DOI: 10.1016/j.cellimm.2014.03.006.Hussein YM, Alzahrani SS, Alharthi AA, Ghonaim MM, Alhazmi AS, Eed EM, Shalaby SM. Association of serum cytokines levels, interleukin 10 -1082G/A and interferon-γ +874T/A polymorphisms with atopic asthma children from Saudi Arabia. Cellular Immunology. 2014;289(1–2):21–26. DOI: 10.1016/j.cellimm.2014.03.006.Keskin O., Keskin M., Kucukosmanoglu E., Ozkars M.Y., Gogebakan B., Kul S., Bayram H., Coskun Y. Exhaled RANTES and interleukin 4 levels after exercise challenge in children with asthma // Annals of Allergy Asthma & immunology. 2012. Vol. 109. No5. P. 303–308. DOI: 10.1016/j.anai.2012.08.009.Keskin O, Keskin M, Kucukosmanoglu E, Ozkars M.Y, Gogebakan B, Kul S, Bayram H, Coskun Y. Exhaled RANTES and interleukin 4 levels after exercise challenge in children with asthma. Annals of Allergy Asthma & immunology. 2012;109(5):303–308. DOI: 10.1016/j.anai.2012.08.009.

The authors declare that there are no conflicts of interest present.